Clinical trials: Loiasis
Onchocerciasis, Loiasis
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases.
- Conditions
- Onchocerciasis, Loiasis, Mansonelliasis, Healthy Volunteers
- Trial name
- Obi1 (NCT06350851)
- Testing
- Biological samples collection (blood drawing + feces)
- Where
- Cameroon
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Bioaster
Loiasis, Lymphatic Filariasis
Spontaneous Antigenemia in Loiasis
This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood.
- Trial name
- NCT04258670
- Testing
- No intervention
- Where
- Cameroon
- Volunteers
- 86 people
- Sponsor
- Washington University School of Medicine
Onchocerciasis, Loiasis
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips.
- Conditions
- Onchocerciasis, Loiasis, Diagnoses Disease, Neglected Diseases
- Trial name
- EOLoa (NCT04035174)
- Testing
- LTS-2 DEC patch, Skin snips
- Where
- Cameroon
- Volunteers
- healthy volunteers welcome
- Sponsor
- Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Onchocerciasis, Ocular, Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of Moxidectin 2 mg in patients with low intensities of microfilariae of Loa loa.
- Trial name
- EOLoa (NCT04049851)
- Testing
- Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab
- Where
- Cameroon
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Loiasis
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
- Trial name
- STOP-FiLAR (NCT06252961)
- Testing
- Levamisole 3 days, Levamisole 5 days
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 99 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Loiasis With Positive Blood Microfilaremia
Assessment and Treatment of Loiasis With Positive Microfilaremia
Loiasis is a vector-borne filariasis endemic in the forested areas in Central Africa whose incidence and morbi-mortality are poorly understood.
- Trial name
- LoPoMi (NCT06194149)
- Volunteers
- 200 people
- Sponsor
- University Hospital, Angers
Loiasis
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
- Trial name
- NCT05085665
- Testing
- Ivermectin
- Where
- Cameroon
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Loiasis
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
Background: Many people who live in west or central Africa are at risk for infection from a very small worm called Loa loa. This infection is acquired through the bite of a fly. Baby worms called microfilariae live in the blood.
- Trial name
- NCT02644525
- Testing
- Imatinib Mesylate
- Where
- Cameroon
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood.
- Trial name
- NCT01111305
- Testing
- Reslizumab, Diethylcarbamazine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis, Ocular, Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.
- Trial name
- EOLoa (NCT04049630)
- Testing
- LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg
- Where
- Republic of the Congo
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Loiasis
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Background: Loa loa is a small worm that infects people in West and Central Africa. It is spread by the bite of a fly. Adult worms live under the skin and can cause swelling in the arms, legs, and face.
- Trial name
- NCT01593722
- Testing
- Diethylcarbamazine, Ivermectin
- Where
- Cameroon
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)